Cytomegalovirus imm iv /vial
Products billed under this code include Cytogam.
Payment limit per PER VIAL, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Cytogam.
Payment limit per PER VIAL, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cytogam | Kamada Ltd. | 49591-0532-51 | 1 | $1,857.125 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1,857.125 | −$1.696 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted September 17, 2026 |
| 3Q26 | $1,858.821 | +$50.214 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted September 15, 2026 |
| 2Q26 | $1,808.607 | +$0.278 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted September 15, 2026 |
| 1Q26 | $1,808.329 | −$0.316 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted September 15, 2026 |
| 4Q25 | $1,808.645 | −$0.799 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted September 8, 2026 |
| 3Q25 | $1,809.444 | −$2.563 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted March 10, 2026 |
| 2Q25 | $1,812.007 | −$2.101 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted March 10, 2026 |
| 1Q25 | $1,814.108 | −$0.83 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted December 19, 2025 |
| 4Q24 | $1,814.938 | +$2.801 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted June 11, 2025 |
| 3Q24 | $1,812.137 | +$3.915 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted June 11, 2025 |
| 2Q24 | $1,808.222 | +$0.35 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted March 11, 2025 |
| 1Q24 | $1,807.872 | +$140.286 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted December 19, 2024 |
| 4Q23 | $1,667.586 | −$146.609 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted October 10, 2024 |
| 3Q23 | $1,814.195 | −$0.424 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted June 5, 2024 |
| 2Q23 | $1,814.619 | +$45.052 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted February 23, 2024 |
| 1Q23 | $1,769.567 | +$102.859 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted December 6, 2023 |
| 4Q22 | $1,666.708 | +$12.051 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted June 22, 2023 |
| 3Q22 | $1,654.657 | +$128.075 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted June 9, 2023 |
| 2Q22 | $1,526.582 | +$1.124 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted December 14, 2022 |
| 1Q22 | $1,525.458 | −$13.241 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted June 8, 2022 |
| 4Q21 | $1,538.699 | +$18.047 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted June 2, 2022 |
| 3Q21 | $1,520.652 | +$53.637 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted June 2, 2022 |
| 2Q21 | $1,467.015 | $0.00 | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted March 1, 2022 |
| 1Q21 | $1,467.015 | – | PER VIAL | Cytomegalovirus imm iv /vial | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.